---
title: "BRIEF: Star Sports Medicine doubles in heavily oversubscribed IPO"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/285165672.md"
description: "Star Sports Medicine Co. Ltd.在首次公開募股（IPO）中表現出色，股價在交易開始時上漲三倍，最終在午盤時上漲 132%。該公司以每股 98.50 港元出售了 842 萬股，籌集淨收益為 7.58 億港元（9700 萬美元）。香港本地投資者的公開發售超額認購超過 7800 倍，國際發售則超額認購 9.4 倍。Star Sports Medicine 是中國第四大運動醫學植入物和設備供應商，預計在 2024 年佔有約 6.5% 的市場份額。"
datetime: "2026-05-05T07:11:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285165672.md)
  - [en](https://longbridge.com/en/news/285165672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285165672.md)
---

# BRIEF: Star Sports Medicine doubles in heavily oversubscribed IPO

Shares of medical device company **Star Sports Medicine Co. Ltd.** (1609.HK) tripled from their IPO price when trading began on Tuesday, before giving back some of the gains to close up 132% at the midday break.

The company **sold** 8.42 million shares for HK$98.50 each, raising net proceeds of HK$758 million ($97 million). The public offering for local Hong Kong investors was more than 7,800 times oversubscribed, while the international offering was oversubscribed by 9.4 times.

Star Sports Medicine is China’s fourth-largest provider of sports medicine implants and devices, controlling about 6.5% of the market in 2024. The company’s revenue reached 403 million yuan ($59 million) last year, up 23% year-on-year, while its profit jumped 44% to 137 million yuan.

The company plans to use 30% of the IPO proceeds to expand its production capabilities and efficiency. Another 35% will go to R&D, 25% to commercialization, sales, and marketing, and the remaining 10% to general working capital.

_By Lau Chi Hang_

_To subscribe to Bamboo Works weekly free newsletter, click_ _here_

### 相關股票

- [01302.HK](https://longbridge.com/zh-HK/quote/01302.HK.md)
- [159898.CN](https://longbridge.com/zh-HK/quote/159898.CN.md)
- [562600.CN](https://longbridge.com/zh-HK/quote/562600.CN.md)
- [159883.CN](https://longbridge.com/zh-HK/quote/159883.CN.md)

## 相關資訊與研究

- [健世科技核心產品 LuX-Valve Plus 歐洲心血管會議公佈數據](https://longbridge.com/zh-HK/news/287133349.md)
- [貝康醫療 Gems 卵裂胚培養液獲批國家三類醫療器械註冊證](https://longbridge.com/zh-HK/news/286336246.md)
- [中國衞生悉數償還銀行借貸 540 萬元，獲新銀行融資額度 460 萬元](https://longbridge.com/zh-HK/news/286691443.md)
- [百心安 Iberis 多極腎動脈射頻消融導管系統獲準越南註冊](https://longbridge.com/zh-HK/news/286014600.md)
- [Star Media Group Berhad（KLSE:STAR）即將除息，其股息收益率為 4.5%](https://longbridge.com/zh-HK/news/286657568.md)